By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Precision BioSciences today announced that in a reexamination proceeding the US Patent and Trademark Office has rejected claims by Cellectis that Precision infringed on four of its patents.

The USPTO issued its Final Decisions and Right of Appeal Notices in the reexamination of US Patent Nos. 6,833,252; 7,214,536; 6,610,545; and 7,309,605. The patents are owned by the Institut Pasteur and the Universite Pierre et Marie Curie and licensed to Cellectis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.